These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32071728)

  • 1. Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.
    Misra VP; Danchenko N; Maisonobe P; Lundkvist J; Hunger M
    J Clin Mov Disord; 2020; 7():2. PubMed ID: 32071728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
    Danchenko N; Johnston KM; Whalen J
    J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
    Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A
    PLoS One; 2021; 16(2):e0245827. PubMed ID: 33524060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation.
    Danchenko N; Johnston KM; Haeussler K; Whalen J
    J Med Econ; 2021; 24(1):949-961. PubMed ID: 34340647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Simpson DM; Hallett M; Ashman EJ; Comella CL; Green MW; Gronseth GS; Armstrong MJ; Gloss D; Potrebic S; Jankovic J; Karp BP; Naumann M; So YT; Yablon SA
    Neurology; 2016 May; 86(19):1818-26. PubMed ID: 27164716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence on botulinum toxin in selected disorders.
    Zakin E; Simpson D
    Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions.
    Lew MF; Hauser RA; Isaacson SH; Truong D; Patel AT; Brashear A; Ondo W; Maisonobe P; Dashtipour K; Bahroo L; Wietek S
    Clin Park Relat Disord; 2021; 5():100115. PubMed ID: 34888518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice.
    Trosch RM; Misra VP; Maisonobe P; Om S
    Clin Park Relat Disord; 2020; 3():100063. PubMed ID: 34316644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of botulinum neurotoxin type A's intraarticular application in experimental animals.
    Okroša AD; Muñoz-Lora VRM; Matak I; Bach-Rojecky L; Kalinichev M; Lacković Z
    Toxicon X; 2023 Jun; 18():100155. PubMed ID: 37096009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    J Neurol; 2022 Nov; 269(11):5991-6002. PubMed ID: 35842881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study.
    Colosimo C; Charles D; Misra VP; Maisonobe P; Om S;
    J Neurol Sci; 2020 Sep; 416():117015. PubMed ID: 32682125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A therapy for cervical dystonia.
    Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.
    Muthukumar M; Desai K; Abogunrin S; Harrower T; Gabriel S; Dinet J
    Clinicoecon Outcomes Res; 2017; 9():211-229. PubMed ID: 28458568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles.
    Dashtipour K; Wietek S; Rubin B; Maisonobe P; Bahroo L; Trosch R
    J Clin Mov Disord; 2020; 7():8. PubMed ID: 32884828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study.
    Mordin M; Masaquel C; Abbott C; Copley-Merriman C
    BMJ Open; 2014 Oct; 4(10):e005150. PubMed ID: 25324317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA.
    Hefter H; Samadzadeh S; Moll M
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33121133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.
    Dashtipour K; Mari Z; Jankovic J; Adler CH; Schwartz M; Brin MF
    J Neurol Sci; 2019 Oct; 405():116413. PubMed ID: 31494402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis.
    Lazzaro C; Baricich A; Picelli A; Caglioni PM; Ratti M; Santamato A
    J Rehabil Med; 2020 Feb; 52(2):. PubMed ID: 31820010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.
    Trosch RM; Shillington AC; English ML; Marchese D
    J Manag Care Spec Pharm; 2015 Oct; 21(10):854-60. PubMed ID: 26402386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.